Drug Search Results
More Filters [+]

Emixustat

Alternative Names: emixustat, acu-4429
Latest Update: 2023-10-04
Latest Update Note: News Article

Product Description

Mechanisms of Action: RPE65 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Stargardt Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kubota Vision
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Emixustat

Countries in Clinic: Brazil, Canada, Denmark, France, Germany, Italy, Netherlands, South Africa, Spain, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Macular Degeneration|Stargardt Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SeaSTAR

P3

Completed

Macular Degeneration|Stargardt Disease

2022-06-13

Recent News Events